ArticleNeuro-oncology advances
Rapid and profound radiological and plasma ctDNA responses to dabrafenib plus trametinib in BRAF-mutant papillary craniopharyngioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 38-year-old male patient was diagnosed with a BRAF-V600E mutant papillary craniopharyngioma. Due to the neurological and endocrine sequalae from multiple surgeries, irradiation of residual tumor was disregarded. Dabrafenib plus trametinib treatment was started achieving a rapid neurological improvement and a profound radiological response (-92%), still ongoing 9 months later, despite treatment withdrawal after 7.5 months of therapy due to toxicity (grade 3 pyrexia). In parallel, BRAF-V600E mutation ctDNA monitoring in plasma showed a profound and durable response. Additional therapeutic trials evaluating upfront BRAF-targeted therapy to minimize local therapies (including surgery and radiation) are needed. Liquid biopsy should be further explored as a non-invasive way of diagnosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.